
Lends at the checkout: buy-now-pay-later loans for shoppers, paid for by merchants and interest.
Affirm at a glance: how it scores on value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
A mixed picture - strengths and real weaknesses - 18 of 36 checks passed.
What you pay today for what the business produces, measured against AFRM's own history and its peers, never a universal rule.
Fairly priced on some measures, rich on others.
4.1%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 4.1%, the business is throwing off more cash per dollar of market value than its own 6-year median of 3.2% - the cheaper end of its history.
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
| – | Cheaper than its own history (earnings) | no multiple history |
| ✓ | Earnings yield beats a long bond (4%) | 7.6% vs 4.0% |
| ✓ | Better cash yield than its own history | 4.1% vs 3.2% |
| ✓ | Free cash flow yield above 3% | 4.1% vs 3.0% |
| ✕ | Cheap on enterprise value | 45.23 vs 14.00 (peer median) |
| ✕ | Price isn't outrunning growth | no positive three-year earnings growth behind the price |
What the company has actually reported - is it selling more, and is more of it becoming profit?
Growing, but with caveats - revenue +29.6% over the last year.
→Revenue reached $1.4B in 2026, compounding +32% a year since 2023 and the pace is picking up.
→Net income was $1.9B in 2026, against $52M the year before. Earnings per share moved +3598% over the last twelve months.
+30%revenue growth, FY 2026
Shown separately because they would flatten the axis: 2026 earnings +3598% - rebounds off a collapsed prior year.
→Revenue grew +30% in 2026. Each point is one year's change against the year before.
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
| ✕ | Outgrew its sector last year | 29.6% vs 34.1% (sector 70th pct, n=73) |
| ✓ | Sustained growth beats its sector (3 years) | 32.1% vs 17.6% (sector 70th pct, n=55) |
| ✓ | Profits grew last year | 3597.9% vs 0.0% |
| ✓ | Profit growth beats its peers | profitable now after losses three years ago |
| ✕ | Growth is speeding up, not slowing | 1y 29.6% vs 3y 32.1% |
| ✓ | Grew per share, not just in total | 95.0% vs 0.0% |
Whether the growth makes real money - margins, returns on capital, and whether profits turn into cash.
Rare profitability: margins and returns on capital are well above its peers.
→Operating margin widened 220 points to 29% since 2023. After everything, 134 cents of each sales dollar reaches net profit. AFRM doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
→Only 64% of reported profit becomes operating cash. Accounting profit is running ahead of cash collection, which is worth watching in the receivables and inventory lines.
→ROE of 35% on shareholders' capital (ROCE isn't meaningful for this business model).
→69 cents of every sales dollar became free cash in 2026, up 86 points since 2023 - the best conversion in its filed history.
→The biggest claim on each sales dollar is stock compensation, at 21% of revenue (capital spending 17%). That share has fallen since 2023, so the cost of competing is easing.
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
| ✓ | Better net margins than peers | 133.6% vs 18.2% (sector 70th pct, n=77) |
| ✓ | Runs leaner than peers (operating margin) | 28.9% vs 25.6% (sector 70th pct, n=45) |
| ✓ | Actually profitable | TTM net income $1.9B |
| ✓ | Earns well on shareholders' money | 35.2% vs 16.1% (sector 70th pct, n=79) |
| ✓ | Earns a real return on its assets | 12.2% vs 5.0% |
| ✕ | Profits are cash, not accounting | 0.64 vs 0.80 |
The balance sheet stress test: could AFRM survive a bad year?
The balance sheet carries real risk - read the checks before anything else.
→Debt of $9.8B sits against $1.6B of cash, or 1.8x shareholders' equity. Earnings cover interest only 0.9 times, which is thin.
→The company's own capital grew from $2.6B in 2023 to $5.5B (+108%). The business is building book value rather than consuming it.
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
| ✕ | Leverage is under control | 0.65 vs 0.60 |
| ✕ | Debt isn't dominating | 1.79 vs 1.00 |
| ✕ | Debt trending the right way | liabilities are 65.3% of assets vs 64.5% five years ago |
| ✕ | Earnings cover the interest | 0.92 vs 5.00 |
| ✓ | Converts sales to cash better than its sector | 85.3% vs 29.3% (sector 70th pct, n=77) |
| ✓ | Self-funding | TTM free cash flow $993M |
How much cash actually flows back to owners - dividends, buybacks, whether the share count truly falls, and whether what is handed back is affordable.
AFRM returns nothing to owners yet, and the share count keeps rising - every dollar stays in the business.
→Stock compensation ($305M) flows out with nothing returned - the dilution is winning.
→2.3% more shares last year - your stake was diluted by that much.
Both lines start at 100 in 2019, so the gap between them is what each share gained or lost. Share counts are split-adjusted.
→AFRM's share count rose +637% from 2019 to 2026 while revenue per share grew +40%. Holders are further ahead than before, though the gain per share is smaller than the growth in the business.
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
| ✕ | Share count isn't climbing | shares up 18.1% over 3 years |
| ✕ | Buybacks outpace the stock issued to staff | no buybacks against $305M of stock compensation |
| ✕ | Hands cash back to owners | no dividends and no buybacks in the last twelve months |
| ✕ | Meaningful yield to owners (dividends and buybacks) | 0.00 returned, 0.0% of market value |
| ✕ | Buybacks are sustained, not one-off | 0.00 bought back in the last twelve months, 0.00 the year before; no dividend |
| ✕ | Buybacks growing | 0.00 vs 0.00 the year before; no dividend |
What the market is doing about all of the above. This is price behaviour, not a fact about the business - read it as the market's current opinion, scored on six checks like every other chapter. The market is the S&P 500, measured by the SPY ETF with dividends included, over 3 months (63 trading sessions) and 12 months (252).
Mixed signals from the market - some trends up, some rolling over.
Chart by TradingView
→AFRM is in a downtrend. The price is below the band where recent trading settled and that band is still falling, so nothing in the picture has turned yet. It crossed only one session ago, so treat it as unsettled. Both the last two weeks and the month-ago comparison point down as well, so nothing here disagrees with the downtrend. The band drawn for the coming weeks turns downward partway through, so that support is set to thin out from there.
The trend read comes from the daily Ichimoku picture, a standard trend indicator, translated out of its jargon. It builds a band from the midpoints of the last 9, 26 and 52 sessions' highs and lows - in effect, the range where recent trading has settled - and draws that band 26 sessions into the future. Price above the band is an uptrend, below it a downtrend, inside it no trend. Because the band is drawn forward, the support for the next few weeks is already fixed and a change of its direction can be seen coming. We also compare the last two weeks against the last month, and today's price against where it stood a month ago. None of this says anything about the business; it describes the price only, and it is not advice. Where a check says 'the S&P 500', the comparison is with the SPY ETF including dividends, on the same adjusted basis as the stock's own price: short means 3 months, 63 trading sessions; long means 12 months, 252.
| ✕ | Trading above its cloud | 0.00 vs 0.50 |
| ✓ | Long-term trend structure is healthy | 77.09 vs 66.51 |
| ✓ | Rising over 3 months | 13.7% vs 0.0% |
| ✓ | Beating the S&P 500 over 3 months | 13.7% vs 4.7% |
| ✕ | Beating the S&P 500 over 12 months | -19.3% vs 20.0% |
| ✓ | Not in a deep hole | -21.5% from its 52-week high |
What the people running the company do with their own shares - reported to the SEC within two days, classified so pay-plumbing doesn't masquerade as conviction.
→No open-market buying, and $23M of selling across 5 months. Selling alone is a weak signal - much of it is pre-scheduled - but the absence of buying tells you no insider saw the price as a bargain.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Katherine Adkins | Chief Legal Officer | exercise | 4,404 | $98,209 |
| 2026-09-03 | Katherine Adkins | Chief Legal Officer | exercise | 37,260 | $870,021 |
| 2026-09-03 | Katherine Adkins | Chief Legal Officer | SELL | 41,664 | $3M |
| 2026-09-02 | Robert O'Hare | Chief Financial Officer | SELL | 5,886 | $435,682 |
| 2026-09-01 | Katherine Adkins | Chief Legal Officer | tax | 4,795 | $335,362 |
| 2026-09-01 | Katherine Adkins | Chief Legal Officer | exercise | 41,664 | $929,107 |
| 2026-09-01 | Katherine Adkins | Chief Legal Officer | SELL | 23,765 | $2M |
| 2026-09-01 | Katherine Adkins | Chief Legal Officer | SELL | 15,599 | $1M |
| 2026-09-01 | Katherine Adkins | Chief Legal Officer | SELL | 2,300 | $165,301 |
| 2026-09-01 | Robert O'Hare | Chief Financial Officer | tax | 6,101 | $426,704 |
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.